IN2014MN02418A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02418A
IN2014MN02418A IN2418MUN2014A IN2014MN02418A IN 2014MN02418 A IN2014MN02418 A IN 2014MN02418A IN 2418MUN2014 A IN2418MUN2014 A IN 2418MUN2014A IN 2014MN02418 A IN2014MN02418 A IN 2014MN02418A
Authority
IN
India
Prior art keywords
methods
breast cancer
subject
gene expression
evaluating
Prior art date
Application number
Inventor
Sean M Ferree
James Justin Storhoff
Joel S Parker
Charles M Perou
Matthew J Ellis
Philip S Bernard
Torsten O Nielsen
Original Assignee
Nanostring Technologies Inc
Univ North Carolina
Univ Utah Res Found
British Columbia Cancer Agency
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanostring Technologies Inc, Univ North Carolina, Univ Utah Res Found, British Columbia Cancer Agency, Univ Washington filed Critical Nanostring Technologies Inc
Publication of IN2014MN02418A publication Critical patent/IN2014MN02418A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides methods for classifying and for evaluating the prognosis of a subject having breast cancer are provided. The methods include prediction of breast cancer subtype using a supervised algorithm trained to stratify subjects on the basis of breast cancer intrinsic subtype. The prediction model is based on the gene expression profile of the intrinsic genes listed in Table 1. Further provided are compositions and methods for predicting outcome or response to therapy of a subject diagnosed with or suspected of having breast cancer. These methods are useful for guiding or determining treatment options for a subject afflicted with breast cancer. Methods of the invention further include means for evaluating gene expression profiles including microarrays and quantitative polymerase chain reaction assays as well as kits comprising reagents for practicing the methods of the invention.
IN2418MUN2014 2012-05-22 2013-05-22 IN2014MN02418A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650209P 2012-05-22 2012-05-22
US201361753673P 2013-01-17 2013-01-17
PCT/US2013/042157 WO2013177245A2 (en) 2012-05-22 2013-05-22 Nano46 genes and methods to predict breast cancer outcome

Publications (1)

Publication Number Publication Date
IN2014MN02418A true IN2014MN02418A (en) 2015-08-14

Family

ID=49624503

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2418MUN2014 IN2014MN02418A (en) 2012-05-22 2013-05-22

Country Status (12)

Country Link
US (3) US20130337444A1 (en)
EP (1) EP2852689B1 (en)
JP (1) JP6325530B2 (en)
CN (2) CN104704128A (en)
AU (1) AU2013266419B2 (en)
BR (1) BR112014029300A2 (en)
CA (1) CA2874492C (en)
ES (1) ES2763931T3 (en)
IL (1) IL235795B (en)
IN (1) IN2014MN02418A (en)
MX (1) MX369628B (en)
WO (1) WO2013177245A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9631239B2 (en) 2008-05-30 2017-04-25 University Of Utah Research Foundation Method of classifying a breast cancer instrinsic subtype
EP2685988A4 (en) 2011-03-15 2014-08-20 Univ North Carolina METHODS OF TREATING BREAST CANCER WITH ANTHRACYCLINE THERAPY
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
AU2012345789B2 (en) 2011-11-30 2018-02-15 British Columbia Cancer Agency Branch Methods of treating breast cancer with taxane therapy
EP3511423B2 (en) 2012-10-17 2024-05-29 Spatial Transcriptomics AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
HK1222888A1 (en) * 2013-05-13 2017-07-14 Nanostring Technologies, Inc. Methods to predict risk of recurrence in node-positive early breast cancer
LT3013983T (en) 2013-06-25 2023-05-10 Prognosys Biosciences, Inc. Spatially encoded biological assays using a microfluidic device
AU2014317843A1 (en) 2013-09-09 2016-03-24 British Columbia Cancer Agency Branch Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
EP3221469B1 (en) 2014-11-21 2020-01-15 Nanostring Technologies, Inc Enzyme- and amplification-free sequencing
AU2015353747B2 (en) * 2014-11-24 2021-02-25 Bruker Spatial Biology, Inc. Methods and apparatuses for gene purification and imaging
JP2018500895A (en) * 2014-12-09 2018-01-18 キングス・カレッジ・ロンドン Breast cancer treatment with taxane therapy
SG11201707515SA (en) 2015-04-10 2017-10-30 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
WO2017014694A1 (en) * 2015-07-23 2017-01-26 National University Of Singapore Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment
EP4324929B1 (en) 2016-05-16 2025-09-17 Bruker Spatial Biology, Inc. Methods for detecting target nucleic acids in a sample
EP3472359B1 (en) 2016-06-21 2022-03-16 10X Genomics, Inc. Nucleic acid sequencing
WO2018074865A2 (en) * 2016-10-21 2018-04-26 서울대학교병원 Composition and method for breast cancer prognosis prediction
US10415080B2 (en) 2016-11-21 2019-09-17 Nanostring Technologies, Inc. Chemical compositions and methods of using same
KR101950717B1 (en) * 2016-11-23 2019-02-21 주식회사 젠큐릭스 Methods for predicting effectiveness of chemotherapy for breast cancer patients
WO2018144782A1 (en) * 2017-02-01 2018-08-09 The Translational Genomics Research Institute Methods of detecting somatic and germline variants in impure tumors
CN120210336A (en) 2017-10-06 2025-06-27 10X基因组学有限公司 RNA templated ligation
KR102071491B1 (en) * 2017-11-10 2020-01-30 주식회사 디시젠 Breast cancer prognosis prediction method and system based on machine learning using next generation sequencing
KR102893736B1 (en) 2018-05-14 2025-11-28 브루커 스페이셜 바이올로지, 인크. Chemical composition and method of use thereof
WO2020094399A1 (en) * 2018-11-05 2020-05-14 Biontech Diagnostics Gmbh Predictive methods in breast cancer
WO2020240025A1 (en) 2019-05-31 2020-12-03 Cartana Ab Method of detecting target nucleic acid molecules
JP7352937B2 (en) * 2019-07-19 2023-09-29 公立大学法人福島県立医科大学 Differential marker gene set, method and kit for differentiating or classifying breast cancer subtypes
GB201919032D0 (en) 2019-12-20 2020-02-05 Cartana Ab Method of detecting an analyte
EP4107285B1 (en) 2020-02-21 2024-10-09 10X Genomics, Inc. Methods and compositions for integrated in situ spatial assay
US12209273B2 (en) 2020-06-12 2025-01-28 10X Genomics, Inc. Nucleic acid assays using click chemistry bioconjugation
EP3945136A1 (en) * 2020-07-28 2022-02-02 Hospital Clínic de Barcelona In vitro method for the prognosis of patients suffering from her2-positive breast cancer
US12297499B2 (en) 2020-08-17 2025-05-13 10X Genomics, Inc. Multicomponent nucleic acid probes for sample analysis
US12060603B2 (en) 2021-01-19 2024-08-13 10X Genomics, Inc. Methods for internally controlled in situ assays using padlock probes
CA3248919A1 (en) * 2021-12-20 2023-06-29 Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomèdiques August Pi I Sunyer Development and validation of an in vitro method for the prognosis of patients suffering from her2-positive breast cancer
CN117965734B (en) * 2024-02-02 2024-09-24 奥明星程(杭州)生物科技有限公司 Gene marker for detecting hard fibroid, kit, detection method and application

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
EP0773227A1 (en) 1991-09-18 1997-05-14 Affymax Technologies N.V. Diverse collections of oligomers in use to prepare drugs, diagnostic reagents, pesticides or herbicides
EP0916396B1 (en) 1991-11-22 2005-04-13 Affymetrix, Inc. (a Delaware Corporation) Combinatorial strategies for polymer synthesis
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc Nucleic acid analysis techniques
JP2001521753A (en) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド Expression profiles in adult and fetal organs
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6750015B2 (en) * 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
US20020168639A1 (en) * 2000-09-22 2002-11-14 Muraca Patrick J. Profile array substrates
DK3170906T3 (en) 2003-06-24 2018-11-05 Genomic Health Inc PREDICTION OF THE LIKELI REVENUE OF CANCER
AU2004285103A1 (en) * 2003-09-29 2005-05-12 Pathwork Diagnostics, Inc. Systems and methods for detecting biological features
WO2006010150A2 (en) 2004-07-15 2006-01-26 University Of Utah Research Foundation Housekeeping genes and methods for identifying the same
CN101057144A (en) * 2004-09-22 2007-10-17 三路影像公司 Methods and compositions for evaluating breast cancer prognosis
US20090299640A1 (en) 2005-11-23 2009-12-03 University Of Utah Research Foundation Methods and Compositions Involving Intrinsic Genes
EP1963500B1 (en) 2005-12-23 2013-02-13 Nanostring Technologies, Inc. Compositions comprising oriented, immobilized macromolecules and methods for their preparation
AU2006330830B2 (en) * 2005-12-23 2013-01-10 Bruker Spatial Biology, Inc. Nanoreporters and methods of manufacturing and use thereof
US8415102B2 (en) 2007-04-10 2013-04-09 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
CN102395682B (en) * 2007-09-06 2015-09-30 生物治疗诊断股份有限公司 Tumor grade and cancer prognosis
US9631239B2 (en) * 2008-05-30 2017-04-25 University Of Utah Research Foundation Method of classifying a breast cancer instrinsic subtype
US8519115B2 (en) 2008-08-14 2013-08-27 Nanostring Technologies, Inc. Stable nanoreporters
JP5940517B2 (en) * 2010-03-31 2016-06-29 ジヴィドン ダイアグノスティックス ゲゼルシャフト ミット ベシュレンクテル ハフツング Methods for predicting breast cancer recurrence under endocrine therapy

Also Published As

Publication number Publication date
US20230272476A1 (en) 2023-08-31
CN104704128A (en) 2015-06-10
EP2852689B1 (en) 2019-12-11
EP2852689A2 (en) 2015-04-01
BR112014029300A2 (en) 2017-07-25
MX2014014275A (en) 2015-07-06
CA2874492C (en) 2021-10-19
MX369628B (en) 2019-11-14
IL235795B (en) 2020-02-27
IL235795A0 (en) 2015-01-29
AU2013266419A1 (en) 2014-12-11
AU2013266419B2 (en) 2018-09-27
US20200332368A1 (en) 2020-10-22
JP6325530B2 (en) 2018-05-16
EP2852689A4 (en) 2016-05-11
ES2763931T3 (en) 2020-06-01
CA2874492A1 (en) 2013-11-28
JP2015518724A (en) 2015-07-06
WO2013177245A3 (en) 2015-01-29
US20130337444A1 (en) 2013-12-19
WO2013177245A2 (en) 2013-11-28
CN111500718A (en) 2020-08-07

Similar Documents

Publication Publication Date Title
IN2014MN02418A (en)
CY1114993T1 (en) Gene Expression Profile To Predict Breast Cancer Outcomes
MX2019007814A (en) Gene expression profile algorithm and test for determining prognosis of prostate cancer.
EP2663656A1 (en) Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
WO2013006443A3 (en) Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
EA201370063A1 (en) PHOSPHOLYPIDE CANCER
NZ709167A (en) Compositions and methods for diagnosing thyroid tumors
NZ599194A (en) Methods to predict clinical outcome of cancer
NZ621638A (en) Dna methylation in colorectal and breast cancer diagnostic methods
PH12014502410A1 (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
WO2011153545A3 (en) Gene expression signature as a predictor of chemotherapeutic response in breast cancer
HK1222888A1 (en) Methods to predict risk of recurrence in node-positive early breast cancer
MX2013008252A (en) Prognostic signature for colorectal cancer recurrence.
NZ729773A (en) Biomarkers for disease progression in melanoma
BR112015022977A2 (en) methods for predicting risk of metastasis in cutaneous melanoma
RU2010149541A (en) METHOD FOR FORECASTING THE DEVELOPMENT OF METABOLIC SYNDROME IN A PATIENT WITH ABDOMINAL OBESITY
Eapen Relapsed acute lymphoblastic leukemia: Is it crucial to achieve molecular remission prior to transplant?
MX2017004816A (en) Methods for predicting clinical outcomes in subjects afflicted with ulcerative colitis.
RU2012142904A (en) METHOD FOR PREDICING RISK OF PSORIASIS AND PSORIATIC ARTHRITIS DEVELOPMENT
WO2011133500A3 (en) Detection and analysis of epigenetic and genetic changes in tumor tissue
HK1199097A1 (en) Predictors for cancer treatment
UA108260U (en) METHOD OF FORECASTING OSTEOPOROSIS DEVELOPMENT
UA95616U (en) METHOD OF FORECASTING FRAGMENT FRAGMENT
Brennan Quantifying Biomarker Risks and Benefits
Ellis Whole Genome Sequencing for Luminal-Type Breast Cancer